Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. Show more
Location: 7 Golda Meir Street, Ness Ziona, 7403650, Israel | Website: https://www.sol-gel.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
65.19M
52 Wk Range
$4.01 - $26.89
Previous Close
$23.40
Open
$23.94
Volume
51,405
Day Range
$22.67 - $28.99
Enterprise Value
42.08M
Cash
24.29M
Avg Qtr Burn
-1.416M
Insider Ownership
70.00%
Institutional Own.
20.62%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
EPSOLAY® (benzoyl peroxide) Cream Details Papulopustular Rosacea | Approved Update | |
Approved Quarterly sales | ||
SGT-610 (Patidegib) Details Gorlin Syndrome, Basal cell carcinoma | Phase 3 Data readout | |
SGT-210 (Erlotinib) Details Darier Disease, Skin disease/disorder | Phase 1b Data readout |